TY - JOUR
T1 - Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma
AU - Hohaus, Stefan
AU - Di Ruscio, Annalisa
AU - Di Febo, Annalaura
AU - Massini, Giuseppina
AU - D'Alo', Francesco
AU - Guidi, Francesco
AU - Mansueto, Giovanna
AU - Voso, Maria Teresa
AU - Leone, Giuseppe
PY - 2005/3/15
Y1 - 2005/3/15
N2 - Purpose: Glutathione S-transferase P1 (GSTP1) is a member of the GST enzyme superfamily that is important for the detoxification of several cytotoxic drugs and their byproducts. A single nucleotide polymorphism results in the substitution of isoleucine (Ile) to valine (Val) at codon 105, causing a metabolically less active variant of the enzyme. We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkin's lymphoma. Experimental Design: The Ile105Val polymorphism in the GSTP1 gene was analyzed using a PCR-RFLP technique. Ninety-seven patients with Hodgkin's lymphoma were included and associations with patient characteristics and treatment outcome were analyzed. Results: The GSTP1 Ile105Val polymorphism was associated in a dose-dependent fashion with an improved failure-free survival in patients with Hodgkin's lymphoma (P = 0.02). The probability of 5-year survival for patients homozygous for the 105Val/105 Val GSTP1 genotype was 100%, for heterozygous patients 74% (95% confidence interval, 56-85), and for patients homozygous for the 105Ile/105Ile genotype 43% (95% confidence interval, 23-61). The Cox multivariate analysis showed that GSTP1 codon 105 genotype was an independent prognostic factor. Conclusions: The GSTP1 genotype predicts clinical outcome in patients with Hodgkin's lymphoma.
AB - Purpose: Glutathione S-transferase P1 (GSTP1) is a member of the GST enzyme superfamily that is important for the detoxification of several cytotoxic drugs and their byproducts. A single nucleotide polymorphism results in the substitution of isoleucine (Ile) to valine (Val) at codon 105, causing a metabolically less active variant of the enzyme. We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkin's lymphoma. Experimental Design: The Ile105Val polymorphism in the GSTP1 gene was analyzed using a PCR-RFLP technique. Ninety-seven patients with Hodgkin's lymphoma were included and associations with patient characteristics and treatment outcome were analyzed. Results: The GSTP1 Ile105Val polymorphism was associated in a dose-dependent fashion with an improved failure-free survival in patients with Hodgkin's lymphoma (P = 0.02). The probability of 5-year survival for patients homozygous for the 105Val/105 Val GSTP1 genotype was 100%, for heterozygous patients 74% (95% confidence interval, 56-85), and for patients homozygous for the 105Ile/105Ile genotype 43% (95% confidence interval, 23-61). The Cox multivariate analysis showed that GSTP1 codon 105 genotype was an independent prognostic factor. Conclusions: The GSTP1 genotype predicts clinical outcome in patients with Hodgkin's lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=16844367244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16844367244&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-04-1250
DO - 10.1158/1078-0432.CCR-04-1250
M3 - Article
C2 - 15788664
AN - SCOPUS:16844367244
SN - 1078-0432
VL - 11
SP - 2175
EP - 2179
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -